Horses infected with equine infectious anaemia virus (EIAV) have a life-long infection, characterized in the first few months by recurrent viraemia with fever, anaemia, and thrombocytopenia (Cheevers & McGuire, 1988; Clabough et al., 1991) . During viremic episodes, cell-free antigenic variants defined by in vitro neutralizing antibody assays can be isolated from plasma (Kono et al., 1973) . Mutations occurring in the env gene encoding gp90 and gp45 cause these antigenic variants (Montelaro et al., 1984; Payne et al., 1987) . Despite variation of neutralization-sensitive epitopes and other mechanisms of viral escape, most EIAV-infected horses eventually become clinically quiescent carriers (Kono et at., 1976) . That lymphocyte responses are involved in EIAV control is demonstrated by the failure of foals with congenital severe combined immunodeficiency, which lack B and T lymphocytes, to terminate viraemia . Also, EIAV carrier horses treated with immunosuppressive drugs have viraemic episodes (Kono et al., 1976) .
EIAV could be controlled by several potentially protective immune responses including neutralizing antibody, cytotoxic T lymphocytes or antibody-dependent mechanisms of cytotoxicity. Studies of protective immune responses to lentiviruses have emphasized envelope glycoproteins. However, some have demonstrated cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus Gag proteins (Riviere et al., 1989; Johnson et aL, 1991 ; Littaua et aL, 1991 ; Yasuhiro et al., 1993) . Immune responses to epitopes on the gagencoded proteins may be important because the rate of divergence in gag is low compared to env in HIV-1 (Li et al., 1988) and in EIAV (Perry et al., 1992) . The EIAV gag gene contains 1458 nucleotides (nt) encoding a 55K Gag precursor protein (Montelaro et al., 1982; Stephens et at., 1986; Hussain et at., 1988) which is proteolytically cleaved into proteins including p15 matrix, p26 capsid, p 11 nucleocapsid, and p9 of unknown function (Henderson et al., 1987) . A 10K protease encoded by the EIAV pol gene and expressed in Escherichia coli cleaves the Gag precursor to yield p26 (Rushlow et aL, 1992) . To evaluate Gag protein synthesis and processing in eukaryotic cells and to aid the dissection of immune responses to Gag proteins, recombinant vaccinia viruses expressing EIAV Gag proteins and protease were evaluated. Viral RNA for cDNA cloning was isolated (O'Rourke et al., 1991) from EIAV-WSU5, a pathogenic cell cultureadapted strain isolated after three sequential passages of prototype EIAV in horses and then three limiting dilutions in cell cultures . Firststrand synthesis was primed with an oligonucleotide corresponding to nt 2582 to 2599 of prototype EIAV provirus (Kawakami et al., 1987) followed by secondstrand synthesis (Gubler & Hoffman, 1983) . Plasmids made by annealing dG-tailed cDNA to dC-tailed pUC19 were used to transform DH5~ E. coli. Isolated plasmid pEIA5G contained a 2.2 kb EIAV cDNA insert and both strands were sequenced (GenBank accession no. L06609) using the dideoxynucleotide chain termination method. The sequence corresponded to nt 340 to 2578 of prototype provirus ( Fig. 1) with the 1458 nt EIAV-WSU5 gag sequence being identical to that of prototype gag (Kawakami et al., 1987 Kawakami et al,, 1987 ; the complete pol extends to nt 5120) is at the top followed by a cDNA clone of the EIAV-WSU5 gag and 5' pol in pEIA5G and the fragments of pEIA5G used to construct recombinant vaccima viruses, VGag/PR and VGag. RT, Reverse transcriptase. g nucleotide differences in 5' poh an A at position 2058 changing arginine to lysine in the predicted protease sequence, a synonymous C at 2341, and an A at 2441 changing glycine to serine in the predicted reverse transcriptase. By comparison, the WSU5 env gene has 13 nt and six amino acid differences from the 2580 nt of prototype env (McGuire et al., 1990) . Like prototype EIAV, expression of Pol proteins from the WSU5 gag-pol transcript requires a ribosomal frameshift (Stephens et al., 1986) . The frameshift may occur at a heptanucleotide site associated with ribosomal frameshifting in other retroviruses (Hatfield et al., 1992) and predicted for EIAV (Montelaro et al., 1993) ; this is A A A A A A C located 40 nt into the gag-pol gene overlap.
To identify EIAV Gag proteins expressed by recombinant viruses, a monoclonal antibody (MAb) binding p26 was defined. The hybridoma producing MAb EIA6A1, an IgG1 isotype, was derived by fusing spleen cells from a BALB/c mouse immunized with EIAV prototype strain with X63.AG8.653 myeloma cells and cloned twice by limiting dilution (Davis et al., 1983) . This MAb reacted in immunoblots with 55K and 26K EIAV proteins and two other minor proteins ( Fig. 2 a, lane 7) . The specificity of MAb EIA6A1 for p26 was defined by mapping the epitope using overlapping hexamers of the p26 amino acid sequence synthesized on plastic pegs (Geysen et al., 1984; Cambridge Research Biochemicals) .
Significant MAb EIA6A1 binding occurred with hexamers encompassing the amino acid sequence QEISKF-LTD (Table 1) corresponding to amino acids 179 to 187 of processed p26 (Stephens et al., 1986) . This epitope is also in the 83 amino acid C terminus of p26 previously identified as a highly immunogenic domain (Chong et al., 1991) .
To demonstrate that the EIAV 55K Gag precursor was processed by the pol-encoded protease rather than cellular proteases and to have vectors which correctly processed Gag proteins, two recombinant vaccinia viruses were made. VGag contained only the gag gene (Kawakami et aL, 1987) to Sinai-digested p S C l l (Chakrabarti et al., 1985) . Prior to ligation, the 5' overhang resulting from the XbaI digest was filled using the Klenow fragment of D N A polymerase I. The Sinai cloning site in pSC11 is downstream of the P7"5 vaccinia virus promoter and the translation initiation codon for the cloned EIAV gag gene was the first A T G in the SmaI-XbI fragment which was located 72 nt downstream from the Sinai site.
V G a g / P R contained gag and 5' pol genes encoding protease (Fig. 1 ). V G a g / P R was made with an insertion plasmid derived by ligating the Sinai fragment from p E I A 5 G containing nt 394 to 2526 to SmaI-digested pSC11. It was predicted to make the Gag precursor and also to have a ribosomal frameshift to produce a detectable Gag-Pol fusion protein (Stephens et al., 1986) . A control vaccinia virus, VSCll, was made with pSCll without an EIAV cDNA insert. The insertion plasmids were characterized by restriction endonuclease digestion and nucleotide sequencing of all ligation sites. The insertion plasmid, pSCll, also contains the flgalactosidase gene driven by the P l l vaccinia virus promoter (Chakrabarti et al., 1985) and following homologous recombination with vaccinia virus WR strain in infected cells, 5-bromo-4-chloro-3-indolyl-Dgalactopyranoside was added to the agarose overlay allowing visual detection of recombinant virus as a blue plaque. Selected recombinants were plaque-purified three times in BSC-1 cells. The Gag proteins made by recombinant vaccinia viruses were identified by immunoblotting infected cell lysates. HeLa and neonatal equine kidney cells, in wells of a 24-well plate, were infected with 10p.f.u./cell for 24 h. Infected cells were lysed with 0"5 % NP40 in 50 mM-Tris-HC1 pH 8, containing 5 mM-EDTA, 5 mMiodoacetamide, 0.1 mM-TLCK and 1 mM-PMSF for 30rain on ice and centrifuged at 12000g for 5min. Proteins in the supernatant were separated by SDS-PAGE, transferred to nitrocellulose and probed with either MAb or serum from an Arabian horse 60 days after infection with EIAV-WSU5 . Bound primary antibodies were detected with either antimouse or anti-horse immunoglobulin antibodies conjugated to horseradish peroxidase and substrate for chemiluminescence (McGuire et al., 1992) . Cell cultures infected with VGag and VGag/PR produced a 55K protein, identified as the Gag precursor by its size and reactivity in immunoblots with MAb EIA6AI (Fig. 2a,  lanes 1, 2, 4 and 5) . In addition, cell cultures infected with VGag/PR, but not VGag, expressed an 82K protein reactive with MAb EIA6A1 (Fig. 2a, lanes 1 and 4) . This protein corresponded to the predicted truncated Gag-Pol fusion protein beginning with an initiation codon at nt 465, having a ribosomal frameshift in the overlap region, and continuing through nt 2526 to a termination codon 18 nt downstream in pSC11. IfVGag encoded a Gag-Pol fusion protein involving the 244 nt overlap region, it was predicted to be approximately 55K and indistinguishable from the 55K Gag precursor protein by immunoblots using the antibodies described. Reactivity of MAb EIA6A1 with isolated EIAV resulted in a strong p26 band and a weak reaction with the 55K precursor protein (Fig. 2a, lane 7) , presumably because of the low amount of this latter protein in EIAV. Serum antibodies from an EIA¥-infected horse bound both the 55K and 82K proteins in cell lysates whereas serum taken before infection did not bind these proteins (Fig. 2b) . p26 was not demonstrated in any of these immunoblots; however, MAb EIA6A1 bound 41K, 44K, 47K and 50K proteins in lysates from VGag-and VGag/PR-infected HeLa cells (Fig. 2a, lanes 1 and 2) and horse serum antibodies to EIAV bound similar proteins in VGag-and VGag/PRinfected thymidine kinase-negative ( T K ) 143B cells (Fig. 2 b) . Since these partially processed Gag proteins were present in lysates of cells infected with either construct, they did not result from the protease encoded by EIAV pol. It is likely these fragments were generated by cellular or vaccinia virus proteases. Cells infected with a recombinant vaccinia virus expressing HIV-1 gag-pol genes processed the 55K Gag precursor to p24 with three intermediates including p39, p41a and p41b (Gowda et al., 1989a) . Whether these HIV-1 Gag protein intermediates are similar to EIAV Gag proteins described above and attributed to cellular or vaccinia virus proteases is unknown.
Failure to detect p26 in recombinant virus-infected cell lysates prompted an examination of these cells for subviral particles which might contain processed p26 (Gowda et aI., 1989b; Karacostas et al., 1989) . For transmission electron microscopy, equine kidney cells in 25 cm 2 tissue culture flasks were inoculated with 10 p.f.u./cell of either VGag/PR, VGag or VSC11. After 24 h, cells were fixed with 4 % paraformaldehyde/2 % glutaraldehyde in 0.1 M-cacodylate buffer at pH 7.4. Fixed cells were removed by scraping, pelleted in agarose, post-fixed in 1% osmium tetroxide, and embedded in Epon. Ten ultrathin sections from each group were stained with uranyl acetate and lead citrate and examined. Cells infected with VGag/PR had both retrovirus-like particles and vaccinia virus particles that were distinguishable by size and morphology (Fig. 3) . The retrovirus-like particles in VGag/PR-infected cells were not complete and were found free in the cytoplasm and budding from the cell membrane. Budding particles had a double-layered membrane with an electron-lucent centre and ranged from 90 to 110 nm in diameter (Fig.  3) . Their morphology was similar to the particles described in cells infected with recombinant vaccinia virus or baculoviruses expressing the HIV-1 gag gene (Karacostas et al., 1989; Gheysen et al., 1989) . Cells infected with VGag had subviral and vaccinia virus particles similar to those described for VGag/PR whereas cells infected with VSC 11 had vaccinia virus, but no subviral retrovirus-like particles.
To examine subviral particles for p26, they were isolated and immunoblotted as described for cell lysates. Particles were removed from culture medium by centrifugation at 120000 g for 3 h, resuspended in PBS, layered onto a 15 % sucrose cushion, and centrifuged at 120 000 g for 90 rain (Haffar et al., 1991) . Particles from VGag/PRinfected cells, and not from VGag-infected cells, contained processed p26 which reacted with MAb EIA6A1 (Fig. 4) demonstrating that processing of the p26 depended on the viral protease. Presence of capsid protein in EIAV subviral particles here and in HIV-1 particles (Gowda et al., 1989b; Karacostas et al., 1989) may be accounted for by protease cleavage of Gag precursor protein after particle assembly. To determine whether VGag/PR would induce an immune response to EIAV Gag proteins, two horses (Shetland ponies H-472 and H-481) were immunized intradermally in each of four locations with l0 s p.f.u, of VGag/PR and were boosted with the same dose at 4 and 12 months later. Two control horses (Shetland ponies H-479 and H-482) were similarly immunized with VSC11. Sera collected 2 weeks after the last boost were analysed for antibodies to EIAV by immunoblotting. The VGag/ PR-immunized horses produced antibodies to EIAV Gag proteins, particularly p26 (Fig. 5, lanes 1 and 2) . Longer development of these immunoblots demonstrated antibodies to p15 and p l l proteins (data not shown). The VSC11-immunized horses did not produce antibodies to EIAV Gag proteins (Fig. 5, lanes 4 and 5) .
Several conclusions can be drawn from the structural analysis of the EIAV gag and 5' pol genes and the functional and immunological analysis of Gag proteins produced by recombinant vaccinia viruses. (i) Following sequential in vivo passages, the gag precursor sequence was more highly conserved in the clone we sequenced than either the 5' pol or env sequence. (ii) Cells infected with VGag/PR expressing the gag and 5' po! genes produced a predicted 82K Gag-Pol fusion protein demonstrating that the ribosomal frameshift necessary for translation of the protease gene from the gag-pol transcript occurred. (iii) The protease in the 82K Gag-Pol fusion protein was functional in equine cells (the only cell line examined for subviral particles) since the 55K Gag precursor was processed to p26 in subviral particles. This also indicated that the viral protease was unaffected by a naturally occurring mutation changing arginine to lysine. (iv) Expressed Gag proteins were bound by antibodies in serum from an EIAV-infected horse, and horses immunized with VGag/PR produced antibodies which bound EIAV Gag proteins. Based on these results, recombinant vaccinia virus VGag/PR produced functional Gag proteins and can be used further to examine T lymphocyte responses in EIAV carriers.
